南京招聘

RESPONSIBILITY:
Regional Issue Management
? Get admission to Provincial Reimbursement Drug List through government communication, expert authentication, related material preparation and sales’ cooperation at responsible region
? Follow the review and update of Provincial Reimbursement Drug List and Medical Insurance policy change once three months at responsible region
? Lobby the government in new product price application to get optimal price
? Negotiate with government to avoid or mitigate risks of price-cut
Policy and Database Management
? Track the personnel change, structure change, policy change in the government entities and share the information timely
? Collect, analyze and interpret market data, report on findings, recommendations and conclusions
? Set up the database of relevant customers and policies
Non-Government Organization and Industry Associates Communication
? Communicate and work with Non-Government Organization (NGO) and industry association to positively influence policy
? Build and maintain the good relationship with professional associates and KOLs
Cooperation for bidding and AIC’s inspection
? Collect information and prepare relevant material for bidding, then communicate with government and associations
? Assist to heal with AIC’s inspection in the local office and make sure optimal outcome

7. REQUIREMENTS:
？ Industry experiences: Minimum 5 years Pharmaceutical industry working experience
？ Position experiences:
- Minimum 5 years working experience in hospital or pharmaceutical government agency
？ Language Skills: Middle level proficiency in English both oral and written
？ Computer Skills: Working knowledge
？ Mobility: Frequent travel requried (50% is in travel)
？ Other Special requirement:
? Pharmaceutical related policies and regulations knowledge
? Good understanding of business and product knowledge
? Good presentation and analysis skill
? Should be an effective team player who can engender credibility and confidence within the team and with customers; a polished professional presence is essential
? Excellent channel and network management
? A strong understanding and solving of market access issues in the Pharmaceutical Industry

关于艾伯维中国

艾伯维（纽约证交所:ABBV）是一家于2013年1月2日正式成立的全球研究型生物制药公司，从雅培公司拆分而来。 艾伯维将尖端生物科技与百年传承的专注、激情，以及专业技术和组织架构集于一身，凭借其专业技术、敬业的员工和独特的创新方式，旨在研发并推广先进治疗方法，解决世界范围内的一些疑难杂症。2013年，全新成立的艾伯维在全球范围内拥有近21,000名员工，产品销往170多个国家。

艾伯维已在中国正式注册成为一家外商独资的医药公司,并且于2013年6月1日完成与雅培中国的拆分。艾伯维中国的产品线涉及多个疾病领域，涵盖免疫学领域、抗病毒学领域、肾脏学领域以及麻醉学领域。同时，艾伯维与中国的医学界和政府部门紧密合作，共同开展覆盖丙肝、肿瘤、免疫学、神经科学、疼痛和妇科健康等领域的临床研究。

艾伯维中国介绍

中国总部    上海

研发中心    艾伯维中国研发中心——上海张江研发中心，落成于2009年3月，是艾伯维全球7个研发中心之一。作为临床前研究的一环，支持全球药品研发中心（GPRD）的药物研发，主要集中在免疫、疼痛、神经系统与肾病领域。

员工数    近500名

历史 艾伯维中国成立于2013年6月1日

企业评级

艾伯维被纳入标准普尔500红利经典指数（S&P 500 Dividend Aristocrat Index） ，纳入这一指数的标准是公司股票连续25年以上实现持续增长的现金分红。同时， 艾伯维也被纳入标准普尔高产红利经典指数（S&P High Yield Dividend Aristocrats Index） ，纳入这一指数的标准是连续20年以上实现持续增长的现金分红。

官方网址    *****************